← Back to Search

[18F]F-AraG PET Tracer Imaging for Cancer

Phase 1
Recruiting
Led By Robert R Flavell, M.D., Ph.D.
Research Sponsored by CellSight Technologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Cancer patients with identified tumor mass
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 weeks before immunotherapy is administered
Awards & highlights

Study Summary

This trial is to study how well a PET tracer called [18F]F-AraG (VisAcT) works in cancer patients who will also receive immunotherapy and/or radiation therapy.

Who is the study for?
This trial is for adult cancer patients who have a detectable tumor mass and are scheduled to receive immunotherapy or radiation therapy. It's not open to those under 18, pregnant or breastfeeding women, or individuals with substance abuse issues.Check my eligibility
What is being tested?
The study is testing the distribution in the body of a PET tracer called [18F]F-AraG (VisAcT) among cancer patients. This Phase 1 trial aims to understand how this tracer travels and accumulates in tissues when patients are treated with immunotherapy or radiation.See study design
What are the potential side effects?
As this is an imaging study using a PET tracer, side effects may include reactions at the injection site, potential allergic reactions to the tracer, and exposure to radiation from the PET scan itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a tumor that can be seen or measured.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 weeks before immunotherapy is administered
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 weeks before immunotherapy is administered for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Visualize biodistribution of the PET tracer [18F]F-AraG post start of immunotherapy
Visualize biodistribution of the PET tracer [18F]F-AraG pre-immunotherapy

Find a Location

Who is running the clinical trial?

CellSight Technologies, Inc.Lead Sponsor
17 Previous Clinical Trials
281 Total Patients Enrolled
UCSF Imaging Center at China BasinUNKNOWN
Robert R Flavell, M.D., Ph.D.Principal InvestigatorUCSF Department of Radiology & Biomedical Imaging

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT03142204 — Phase 1
Cancer Research Study Groups:
Cancer Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT03142204 — Phase 1
Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT03142204 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To whom is participation in this experiment available?

"This investigation is open to 30 volunteers aged between 18 and 65 who possess malignant afflictions. Furthermore, the trial demands that participants are scheduled to receive immunotherapy or radiation therapy."

Answered by AI

What is the upper limit for participant registration in this medical trial?

"Affirmative. A perusal of clinicaltrials.gov reveals that this research project, which was initially publicized on May 1st 2017, is actively enrolling volunteers. Approximately 30 participants need to be sourced from a single medical hub."

Answered by AI

Has this particular therapeutic approach received authorization from the FDA?

"As this is a Phase 1 clinical trial, the level of safety associated with this treatment has been estimated to be a score of 1 due to limited evidence that supports its efficacy and security."

Answered by AI

Is the research team currently seeking participants?

"As noted on clinicaltrials.gov, this medical study is actively seeking patients. It was first shared publicly on May 1st 2017 and the last update occurred August 2nd 2021."

Answered by AI

Are youthful participants being admitted for participation in this experiment?

"Those that wish to participate in this medical research must be between 18 and 65 years of age."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy
2017. "[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03142204.
~0 spots leftby May 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top